Compare GSK plc (GSK) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wendys Co — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Wendys Co trades at $6.23 (market cap $1.19B). The key difference: GSK plc is far larger — about 77.2× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Wendys Co for 77 Days on average.
| GSK | WEN | |
|---|---|---|
Market Cap | $91.88B | $1.19B |
Volume | 7,730,529 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $9.33 |
52-Week Low | $43.24 | $6.10 |
Typical Hold Time | 93 Days | 77 Days |
Enterprise Value | $111.88B | $4.92B |
Dividend Yield | 3.9% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Wendy's (WEN) trades at $6.22, up 1.8% today but remains in a bearish technical trend with declining fundamentals. Revenue has stagnated around $2.2B, while net income fell to $165M in 2025, with a projected drop to $126M in 2026. The stock appears undervalued with a P/E of 9.45 and P/S of 0.54, but faces headwinds from a major franchisee bankruptcy and six consecutive quarters of same-store sales declines.
The outlook is cautious due to operational challenges and high debt, though the low valuation and consistent dividend offer some support. Analyst consensus is a 'Hold' with a $7.58 price target, reflecting skepticism about near-term recovery. Key risks include competitive pressure, execution missteps, and macroeconomic strain on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
